
LAVA Therapeutics NV
NASDAQ:LVTX

Intrinsic Value
The intrinsic value of one
LVTX
stock under the Base Case scenario is
2
USD.
Compared to the current market price of 1.3 USD,
LAVA Therapeutics NV
is
Undervalued by 35%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
LAVA Therapeutics NV
Fundamental Analysis


Revenue & Expenses Breakdown
LAVA Therapeutics NV
Balance Sheet Decomposition
LAVA Therapeutics NV
Current Assets | 81.5m |
Cash & Short-Term Investments | 78.9m |
Receivables | 1m |
Other Current Assets | 1.6m |
Non-Current Assets | 1.8m |
PP&E | 1.7m |
Other Non-Current Assets | 114k |
Free Cash Flow Analysis
LAVA Therapeutics NV
USD | |
Free Cash Flow | USD |
Earnings Waterfall
LAVA Therapeutics NV
Revenue
|
7.3m
USD
|
Cost of Revenue
|
-154k
USD
|
Gross Profit
|
7.2m
USD
|
Operating Expenses
|
-35.2m
USD
|
Operating Income
|
-28m
USD
|
Other Expenses
|
397k
USD
|
Net Income
|
-27.6m
USD
|
LVTX Profitability Score
Profitability Due Diligence
LAVA Therapeutics NV's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Score
LAVA Therapeutics NV's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
LVTX Solvency Score
Solvency Due Diligence
LAVA Therapeutics NV's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Score
LAVA Therapeutics NV's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LVTX Price Targets Summary
LAVA Therapeutics NV
According to Wall Street analysts, the average 1-year price target for
LVTX
is 2.21 USD
with a low forecast of 1.52 USD and a high forecast of 3.15 USD.
Dividends
Current shareholder yield for LVTX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
LVTX
stock under the Base Case scenario is
2
USD.
Compared to the current market price of 1.3 USD,
LAVA Therapeutics NV
is
Undervalued by 35%.